Literature DB >> 15611778

Building an antibody factory: a job for the unfolded protein response.

Joseph W Brewer1, Linda M Hendershot.   

Abstract

Plasma cells are highly specialized, terminally differentiated secretory cells that produce tremendous quantities of a single product, the antibody molecule. In differentiating from a quiescent B cell, the plasma cell must undergo a dramatic architectural metamorphosis. This process entails augmenting the secretory organelles and the proteins that populate them, upregulating their energy and translation potential, and increasing the quality control system to do the job. This transformation is accomplished by an interplay between B lineage-specific transcriptional programs that control plasma cell differentiation and an unfolded protein response.

Mesh:

Year:  2005        PMID: 15611778     DOI: 10.1038/ni1149

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  38 in total

Review 1.  Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses.

Authors:  Egest J Pone; Hong Zan; Jingsong Zhang; Ahmed Al-Qahtani; Zhenming Xu; Paolo Casali
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

2.  Improved antibody production in Chinese hamster ovary cells by ATF4 overexpression.

Authors:  Ahmad M Haredy; Akitoshi Nishizawa; Kohsuke Honda; Tomoshi Ohya; Hisao Ohtake; Takeshi Omasa
Journal:  Cytotechnology       Date:  2013-09-13       Impact factor: 2.058

3.  Reovirus induces and benefits from an integrated cellular stress response.

Authors:  Jennifer A Smith; Stephen C Schmechel; Arvind Raghavan; Michelle Abelson; Cavan Reilly; Michael G Katze; Randal J Kaufman; Paul R Bohjanen; Leslie A Schiff
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  Using cell engineering and omic tools for the improvement of cell culture processes.

Authors:  Darrin Kuystermans; Britta Krampe; Halina Swiderek; Mohamed Al-Rubeai
Journal:  Cytotechnology       Date:  2007-02-24       Impact factor: 2.058

5.  Inhibition of cyclooxygenase-2 impairs the expression of essential plasma cell transcription factors and human B-lymphocyte differentiation.

Authors:  Matthew P Bernard; Richard P Phipps
Journal:  Immunology       Date:  2010-01       Impact factor: 7.397

6.  Efficient IgM assembly and secretion require the plasma cell induced endoplasmic reticulum protein pERp1.

Authors:  Eelco van Anken; Florentina Pena; Nicole Hafkemeijer; Chantal Christis; Edwin P Romijn; Ulla Grauschopf; Viola M J Oorschot; Thomas Pertel; Sander Engels; Ari Ora; Viorica Lástun; Rudi Glockshuber; Judith Klumperman; Albert J R Heck; Jeremy Luban; Ineke Braakman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-17       Impact factor: 11.205

7.  In vivo crystallization of human IgG in the endoplasmic reticulum of engineered Chinese hamster ovary (CHO) cells.

Authors:  Haruki Hasegawa; John Wendling; Feng He; Egor Trilisky; Riki Stevenson; Heather Franey; Francis Kinderman; Gary Li; Deirdre Murphy Piedmonte; Timothy Osslund; Min Shen; Randal R Ketchem
Journal:  J Biol Chem       Date:  2011-04-04       Impact factor: 5.157

8.  Factor VIII delivered by haematopoietic stem cell-derived B cells corrects the phenotype of haemophilia A mice.

Authors:  Ali Ramezani; Lynnsey A Zweier-Renn; Robert G Hawley
Journal:  Thromb Haemost       Date:  2011-01-25       Impact factor: 5.249

9.  The unfolded protein response of B-lymphocytes: PERK-independent development of antibody-secreting cells.

Authors:  Jennifer N Gass; Hao-Yuan Jiang; Ronald C Wek; Joseph W Brewer
Journal:  Mol Immunol       Date:  2007-09-05       Impact factor: 4.407

10.  XBP-1, a novel human T-lymphotropic virus type 1 (HTLV-1) tax binding protein, activates HTLV-1 basal and tax-activated transcription.

Authors:  Sebastian C Y Ku; Jialing Lee; Joanne Lau; Meera Gurumurthy; Raymond Ng; Siew Hui Lwa; Joseph Lee; Zachary Klase; Fatah Kashanchi; Sheng-Hao Chao
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.